Phaseline

Targets › CDK1

CDK1 (Cyclin-dependent kinase 1): drug programs, companies and trials

2 programs from 1 company in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.

Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition via association with multiple interphase cyclins. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, ASB7, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1…. (UniProt, P06493)

Open in Phaseline: the race on CDK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Dinaciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor
CDK1, CDK2, CDK5, CDK9Phase 2Acral Lentiginous Melanoma; Advanced Malignant Solid NeoplasmMar 2027
National Cancer Institute (NCI)Zotiraciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor
CDK1, CDK2, CDK7, CDK9, FLT3Phase 1Brain TumorAug 2028

Conditions

Brain Tumor (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1)

Modalities

small molecule (2)

Companies

National Cancer Institute (NCI) (2)

Related targets

CDK2 (2) CDK9 (2) CDK7 (1) FLT3 (1) CDK5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.